Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The pharmaceutical sector has underperformed compared to the broader market, with a decline of 2.78% over the past week, while the Shanghai Composite Index fell by 1.07% [10]. - The report highlights that 42 companies will be included in the Hong Kong Stock Connect on March 9, 2026, with 13 from the biopharmaceutical and healthcare sectors, which is expected to enhance trading liquidity and shareholder structure [4][11]. - The current valuation of the pharmaceutical sector is 33.3 times PE based on 2026 earnings forecasts, representing a 26% premium over the overall A-share market (excluding financials) [4][11]. Summary by Sections 1. Industry Performance - The pharmaceutical sector ranks 17th among 31 primary sub-industries, with specific sub-sectors like medical services and biological products experiencing significant declines [10]. - Year-to-date, the pharmaceutical sector has yielded a return of 0.10%, lagging behind the Shanghai Composite Index's return of 0.66% [4][10]. 2. Market Dynamics - The report notes that the pharmaceutical sector's performance has been affected by various factors, including recent policy adjustments and market sentiment [4][10]. - The report emphasizes the ongoing innovation in domestic pharmaceutical companies, which is expected to drive future growth [4]. 3. Valuation Metrics - The TTM (Trailing Twelve Months) PE ratio for the pharmaceutical sector is currently at 30.5, which is below the historical average of 34.9 [4][11]. - The report indicates that the pharmaceutical sector's valuation is relatively attractive compared to the overall market, suggesting potential investment opportunities [4][11]. 4. Key Companies to Watch - The report identifies several companies to focus on, including Aidi Pharmaceutical, WuXi Biologics, and others, which are expected to benefit from the current market dynamics [4][5].

Group 1 - The report highlights the strong performance of the wind power hydraulic lubrication leader, Chuanrun Co., which is advancing into AIDC liquid cooling, benefiting from the rising industry demand [4] - The company has a solid global layout in high-end energy equipment manufacturing, focusing on offshore wind power and liquid cooling, with overseas revenue reaching 43.64 million yuan in the first half of 2025, a year-on-year increase of 375.7% [4] - The liquid cooling technology is expected to gain traction due to stricter energy consumption regulations for data centers, with NVIDIA's next-generation Rubin chip adopting a fully liquid cooling solution, enhancing market potential [5][6] Group 2 - The asset allocation report emphasizes the continuity of the policy framework for 2026, with a focus on expanding domestic demand and managing financial risks in real estate and local debts [8][9] - The macroeconomic environment is supported by a strong fiscal policy and moderate monetary easing, which is expected to stabilize the equity market [9] - The report outlines a shift towards more execution-oriented industrial policies, enhancing visibility for commercial applications and orders in various sectors [9] Group 3 - The AI demand is projected to exceed expectations, with Shengquan Group positioned to benefit from the high-performance resin market, which is expected to see rapid growth [11] - The company is the largest domestic supplier of electronic chemical materials, with a comprehensive product matrix for high-frequency and high-speed copper-clad laminates [12] - Shengquan Group is expanding its production capacity with new projects set to come online in 2026, including 2000 tons/year of PPO/OPE resin and 1500 tons/year of hydrocarbon resin [12] Group 4 - The automotive industry report discusses the competitive landscape of Robotaxi in the US and China, highlighting Waymo and Tesla as key players in the US market [16][17] - In China, companies like Pony.ai and WeRide are leading the Robotaxi sector, with significant advancements in operational areas and regulatory support for autonomous driving [18] - The report suggests investment opportunities in leading Robotaxi companies and related technologies, emphasizing the acceleration of commercialization in both markets [19] Group 5 - The macroeconomic commentary on the government work report for 2026 outlines a growth target of 4.5%-5%, with a focus on expanding domestic demand and optimizing supply [20][22] - The report emphasizes the importance of employment, with a target of over 12 million new urban jobs, aligning with the economic growth objectives [23] - The fiscal policy remains proactive, with a projected budget expenditure of 30 trillion yuan for 2026, reflecting a commitment to sustainable growth [25][26] Group 6 - The report indicates a strong emphasis on technology innovation as a driver for new economic momentum, with significant increases in R&D investment expected [36][37] - The focus on high-level self-reliance in technology is set to support the development of new industries and enhance the digital economy's contribution to GDP [37][38] - The report outlines plans for substantial investments in modernizing the industrial system, with a focus on high-quality development and technological advancements [38]

Investment Rating - The report maintains a "Recommended" rating for the computer industry, indicating a favorable outlook for the sector [1]. Core Insights - The upcoming NVIDIA GTC 2026 conference is expected to unveil a new AI inference chip system, integrating the LPU architecture from NVIDIA's acquisition of Groq, aimed at optimizing inference performance [5]. - The global demand for computing power is shifting from training to inference, with significant implications for the market structure and opportunities for domestic chip manufacturers [8]. - The report emphasizes the acceleration of domestic infrastructure development for AI inference, suggesting a broad growth opportunity for related AI chip, hardware, and service companies [8]. Summary by Sections Recent Performance - The computer industry has shown mixed performance over the past year, with a 1-month decline of 0.6%, a 3-month increase of 4.4%, and a 12-month decline of 1.3% [3]. Upcoming Events - The NVIDIA GTC 2026 conference will take place from March 16 to 19 in San Jose, California, featuring key advancements in AI technologies, including new AI acceleration chips and systems [5]. Technological Developments - The Groq LPU is designed for inference acceleration, utilizing SRAM for model parameter storage, which significantly enhances data processing speed compared to traditional GPU architectures [6][7]. Market Trends - By 2032, the proportion of training costs in large cloud computing companies' data center expenditures is expected to drop from over 40% to around 14%, indicating a clear shift towards inference [8]. - Major companies are securing large-scale orders for inference-optimized chips, highlighting the growing demand for such technologies [8]. Investment Strategy - The report suggests a focus on specific stocks within the AI chip sector, including companies like Haiguang Information, Cambrian, and others, as well as those involved in servers and liquid cooling technologies [8].

Investment Rating - The industry investment rating is "Recommended" (maintained) [1] Core Viewpoints - The new materials sector is a crucial direction for the future development of the chemical industry, currently experiencing rapid growth in downstream demand. With policy support and technological breakthroughs, domestic new materials are expected to accelerate their long-term growth. The report emphasizes that "one generation of materials leads to one generation of industries," highlighting the foundational nature of the new materials industry for other sectors [5][16]. Summary by Relevant Sections 1) Electronic Information Sector - Focus on semiconductor materials, display materials, and 5G materials [6] - The demand for high-speed transmission in data centers is increasing due to the rise of generative AI, with Micro LED CPO solutions expected to significantly reduce energy consumption compared to traditional copper cable solutions [7][25]. 2) Aerospace Sector - Key areas of interest include PI films, precision ceramics, and carbon fibers [8]. 3) New Energy Sector - Focus on photovoltaic materials, lithium-ion batteries, proton exchange membranes, and hydrogen storage materials [10]. - In January 2026, there were 5,690 new renewable energy projects registered, with 5,618 being photovoltaic projects [11]. 4) Biotechnology Sector - Key areas of interest include synthetic biology and scientific services [12]. - Recent government opinions indicate a push for technology insurance to support high-risk R&D in fields like synthetic biology, highlighting its strategic importance [13]. 5) Energy Conservation and Environmental Protection Sector - Focus on adsorbent resins, membrane materials, and biodegradable plastics [14]. - The government aims to promote green and low-carbon economies, with plans for a national low-carbon transition fund [15]. 6) Key Companies and Profit Forecasts - The report lists several key companies with their stock prices and earnings per share (EPS) forecasts for 2024, 2025, and 2026, along with their investment ratings [17]. - Notable companies include: - Ruihua Tai (688323.SH) with a projected EPS of 0.26 in 2026 and a rating of "Increase" [17]. - Guangwei Composite (300699.SZ) with a projected EPS of 1.09 in 2026 and a rating of "Buy" [17]. - Wanrun Co. (002643.SZ) with a projected EPS of 0.58 in 2026 and a rating of "Buy" [17].

Investment Rating - The report maintains a "Recommended" rating for the chemical industry [1][28]. Core Insights - The global chemical industry is entering a significant upward cycle driven by anti-involution and AI demand, with China's leading companies benefiting from solid cost and efficiency advantages. The industry is expected to see a substantial increase in free cash flow as capacity expansion slows, transforming companies from cash-consuming entities to cash-generating ones. The upcoming peak season for chemicals is anticipated to enhance profitability, making it crucial to focus on demand, value, and supply dynamics for investment opportunities [3][28]. Summary by Sections Recent Trends - As of March 5, 2026, the Guohai Chemical Prosperity Index stands at 99.35, reflecting a 5.16 increase from February 26, 2026 [1]. Performance Metrics - The basic chemical sector has shown a performance increase of 7.4% over the past month, 23.6% over the past three months, and 50.8% over the past year [4]. Investment Opportunities 1. **Value-Driven Opportunities**: Potential for increased dividend yields in sectors such as coal chemicals (e.g., Hualu Hengsheng, Luxi Chemical), oil refining (e.g., Hengli Petrochemical, Sinopec), pesticides (e.g., Yangnong Chemical), and potassium fertilizers (e.g., Salt Lake Industry) [3]. 2. **Supply-Driven Opportunities**: Focus on domestic anti-involution policies and European capacity exits, with key players including PTA/Polyester (e.g., Xinfengming, Tongkun), glyphosate and organosilicon (e.g., Xingfa Group), and industrial silicon (e.g., Hoshine Silicon) [6]. 3. **Demand-Driven Opportunities**: Highlighting sectors benefiting from large-scale opportunities, including gas turbines (e.g., Zhenhua Group), refrigerants (e.g., Juhua), and energy storage (e.g., Chuanheng) [6]. Key Companies and Earnings Forecasts - The report tracks several key companies with their respective earnings per share (EPS) forecasts for 2024 to 2026, indicating a positive outlook for many, including Dongfang Shenghong, Hubei Yihua, and Wanhua Chemical [29]. Market Observations - The report notes that geopolitical tensions, particularly in the Middle East, are likely to drive oil prices higher, benefiting companies like China National Petroleum and CNOOC, while also increasing costs for petrochemical products [9][13]. Price Trends - Recent price increases have been observed in various chemical products, including MDI and TDI, with significant upward movements in raw material costs due to geopolitical events [14][18]. Conclusion - The chemical industry is positioned for a favorable outlook, driven by structural changes in supply and demand dynamics, with a focus on companies that can leverage these trends for growth and profitability [28].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][9] Core Views - The report highlights that the rise in oil prices has significantly enhanced the company's performance elasticity, and the high-end polyolefin projects are expected to unlock long-term growth potential [2][6] - The company is positioned as a leading integrated producer in the light hydrocarbon industry, establishing a self-controlled global supply chain for light hydrocarbons [6][9] - The α-olefin comprehensive utilization project is anticipated to expand the company's upstream ethylene production capacity and support the development of high-end new materials [7][9] Financial Performance - As of March 6, 2026, the company's market data shows a total market capitalization of approximately 90.65 billion and a current price of 26.91 yuan, with a 52-week price range of 15.54 to 26.91 yuan [3] - The company is projected to achieve revenues of 530.21 billion, 686.16 billion, and 813.68 billion yuan for the years 2025, 2026, and 2027 respectively, with corresponding net profits of 52.05 billion, 75.01 billion, and 87.31 billion yuan [9][16] - The expected growth rates for revenue are 10%, 16%, 29%, and 19% for the years 2024 to 2027 [8][9] Market Dynamics - The report notes that the price of key products has increased significantly, with acrylic acid averaging 7950 yuan/ton (up 33.61% week-on-week) and butyl acrylate at 10000 yuan/ton (up 28.21% week-on-week) as of March 6, 2026 [4][9] - The U.S. ethane supply is expected to remain ample, with prices at 22.8 cents per gallon (up 5.56% week-on-week), benefiting from the shale gas revolution [5][9] Strategic Initiatives - The company is advancing its high-end polyolefin projects, which are expected to contribute to significant profit growth, with a focus on new materials such as polyethylene elastomers and ultra-high molecular weight polyethylene [7][9] - The construction of the α-olefin comprehensive utilization high-end new materials industrial park is set to begin in Q2 2024, with a total planned investment of approximately 266 billion yuan [7][9]

1. Report Industry Investment Rating - The report does not mention the industry investment rating. 2. Core Viewpoints of the Report - The bond market has shown low - volatility oscillations this week. Over the past two months, the bond market has recovered to some extent, with the 10 - year Treasury bond yield dropping from 1.90% on January 7th to 1.78% on March 6th [6][12]. - The 10 - year tax spread has not compressed despite the decline in interest rates. As of March 6th, the spread was 17.85bp, at the 97.2% high - percentile point since 2024. The weak performance of China Development Bank bonds may be related to the change in the capital flow of the public - offering funds' liability side and their "over - defensive" mindset [6][12]. - The tax spreads of 3 - year, 5 - year, and 7 - year bonds have improved. If the optimistic sentiment in the bond market continues, there is a large compression space for the 10 - year China Development Bank bond tax spread [6][13]. - Banks are increasing the trading volume of 10 - year China Development Bank bonds. The profit - taking power of banks cannot be ignored [6][13]. - Maintain the previous view that the bond market can be more optimistic. If there is a need to extend the duration, the active bonds of 10 - year China Development Bank bonds and 30 - year Treasury bonds are still good choices [7][13]. 3. Summary by Relevant Catalog 3.1 This Week's Bond Market Review - The bond market showed low - volatility oscillations this week. In the past two months, it has recovered, and the 10 - year Treasury bond yield declined from 1.90% on January 7th to 1.78% on March 6th [6][12]. - The 10 - year tax spread did not compress. As of March 6th, it was at a high - percentile point. The weak performance of China Development Bank bonds may be due to the capital flow change of public - offering funds' liability side and their defensive mindset. From the beginning of the year to March 6th, public - offering funds only net - bought 238 billion yuan of 10 - year China Development Bank bonds in the secondary market, while the net - buying of other 3 - 5 - year bonds (mainly Tier 2 and perpetual bonds) reached 2075 billion yuan. Also, the pure - bond funds are in a defensive state [6][12]. 3.2 Outlook on Future Market Trends - The tax spreads of 3 - year, 5 - year, and 7 - year bonds have improved. From February 28th to March 6th, their quantiles have decreased. The 10 - year China Development Bank bond spread quantile is still at a high level, and if the market sentiment improves, there is a large compression space [6][13]. - Banks are increasing the trading volume of 10 - year China Development Bank bonds. From March 2nd to March 6th, securities firms, funds, and other institutions have increased their allocations, and large - scale banks' net - selling is more significant. The profit - taking power of banks cannot be ignored [6][13]. - Maintain the view that the bond market can be more optimistic. For duration extension, the active bonds of 10 - year China Development Bank bonds and 30 - year Treasury bonds are good choices [7][13].

Investment Rating - The report maintains a "Recommended" rating for the humanoid robotics industry [1] Core Insights - The report highlights the importance of developing embodied intelligence as emphasized in the recent Two Sessions, indicating that by 2025, China aims to lead in robotics, quantum technology, and artificial intelligence applications. The focus will be on optimizing traditional industries and nurturing emerging sectors [5][6] - The humanoid robotics industry is expected to experience significant investment opportunities as it transitions from 0 to 1, with the potential to open up broader market spaces beyond automotive applications [12] - The report suggests that the humanoid robotics sector may be on the verge of a "ChatGPT moment," indicating a pivotal shift in technology and market dynamics [12] Industry Dynamics - Recent developments include the completion of several financing rounds by companies in the humanoid robotics sector, such as KNOWIN, which raised over 2 billion RMB, and Xingdong Jiyuan, which achieved a valuation exceeding 10 billion RMB [6][8] - Strategic partnerships are forming, such as the collaboration between Schaeffler and Chinese robotics company Leju, aimed at advancing humanoid robotics applications in industrial settings [6] - The report emphasizes the ongoing product iterations and rapid business collaborations within the humanoid robotics supply chain, which are crucial for scaling production and commercial viability [12] Key Companies to Watch - The report identifies several companies with core component expertise and active involvement in humanoid robotics, including: - Sanhua Intelligent Controls (actuator assembly) - Top Group (actuator assembly) - Zhongjian Technology (actuator assembly) - Zhejiang Rongtai (screw rod) - Best (screw rod) - Zhenyu Technology (screw rod) - Beite Technology (screw rod) - Xiamen Precision (screw rod) - Fulian Precision (reducer) - Lide Harmonic (reducer) - Shuanghuan Transmission (reducer) [12]

Investment Rating - The report maintains a "Buy" rating for JD Group-SW (9618.HK) [1] Core Insights - JD Group's Q4 2025 revenue reached 352.3 billion RMB, showing a year-over-year increase of 2% and a quarter-over-quarter increase of 18%, exceeding Bloomberg consensus expectations [4][10] - The adjusted net profit attributable to shareholders for Q4 2025 was 1.1 billion RMB, significantly above Bloomberg consensus expectations [10] - The company reported a total shareholder return of approximately 10% for 2025, with a share buyback amounting to about 3 billion USD and cash dividends of around 1.4 billion USD [4] Summary by Relevant Sections Overall Performance - JD Group's Q4 2025 revenue slightly exceeded expectations, driven by strong advertising revenue from daily necessities and cross-selling in the food delivery segment [6] - The retail segment's revenue decreased by 2% year-over-year to 301.9 billion RMB, impacted by high base effects in the electronics category, while daily necessities grew by 12% [6][10] Profitability - Q4 2025 gross profit was 55.1 billion RMB, with a gross margin of 15.6% [14] - Operating profit was -5.8 billion RMB, reflecting a significant decline year-over-year [14] - The net profit for Q4 was -1.2 billion RMB, with a net margin of -0.3% [14] Future Projections - Revenue forecasts for 2026-2028 are 1.4 trillion, 1.5 trillion, and 1.58 trillion RMB respectively, with expected net profits of 23.7 billion, 36.1 billion, and 47.5 billion RMB [19] - The report anticipates continued improvement in operational efficiency and profitability from the food delivery business [9][19] Valuation - The target market capitalization for JD Group in 2026 is estimated at 432.9 billion RMB, corresponding to a target price of 136 RMB per share [19][20] - The report uses a sum-of-the-parts (SOTP) valuation method to arrive at this target price [19]

Investment Rating - The investment rating for JD Health (6618.HK) is "Buy" (maintained) [1][9] Core Views - JD Health reported strong revenue and profit growth for 2025, with revenue reaching 73.4 billion RMB, a year-on-year increase of 26.3%. Adjusted operating profit was 4.39 billion RMB, up 69% year-on-year, and adjusted net profit was 6.53 billion RMB, a 36% increase [4][5] - The company is actively building a new infrastructure for "AI + supply chain" in healthcare, enhancing its competitive edge in the pharmaceutical supply chain and the synergy between self-operated and platform services [5][8] Financial Performance - In 2025, revenue from pharmaceutical and health products grew by 25% to 60.9 billion RMB, while revenue from online platforms/digital marketing and other services increased by 34% to 12.6 billion RMB [5] - The annual active user count reached 218 million by December 31, 2025, with a net increase of over 34 million users compared to 2024 [5] - As of December 31, 2025, the company's total cash reserves amounted to 69.5 billion RMB [5] Business Development - JD Health launched over 100 new drugs in 2025, significantly increasing from over 30 in 2024, aiming to become the "first stop for new drug launches" [5] - The company has over 7,000 health supplement brands that have seen continuous sales growth for three consecutive years, focusing on high-potential categories such as infant development and anti-aging [5] - The instant retail business is rapidly developing, with over 300 self-operated pharmacy stores opened, and the JD Home Health Check service saw an 81.9% increase in order volume in 2025 [5][8] Future Projections - Revenue projections for 2026-2028 are 87.4 billion RMB, 100.4 billion RMB, and 112.2 billion RMB, respectively, with adjusted net profits of 6.64 billion RMB, 7.48 billion RMB, and 8.21 billion RMB [7][8] - The company is expected to benefit from the increasing online penetration of pharmaceuticals and the expansion of online medical insurance payment services [8]